Objective. To compare the activity of high-density lipoprotein (HDL)-associated paraoxonase 1 (PON1) in patients with psoriasis (PsO) and patients with psoriatic arthritis (PsA), and to evaluate the association of PON1 activity with the extent of disease activity and severity of the cardiovascular disease (CVD) burden in these patients.
no correlation was seen between serum arylesterase activity and the extent of disease activity or CVD burden in patients with PsO. Serum paraoxonase activity trended lower both in patients with PsO and in patients with PsA (each P = 0.073 versus healthy controls). However, no association was seen between serum paraoxonase activity and the extent of disease activity or CVD burden in either of the patient cohorts.
Conclusion. PON1 activity is decreased in psoriatic diseases. In the PsA cohort, decreases in arylesterase activity correlated with increasing severity of joint disease and CVD burden. Arylesterase activity, as compared to paraoxonase activity, appeared to serve as a more sensitive predictor of preexisting CV risk factors in the PsA cohort. However, this correlation was not observed in the PsO population.
Psoriatic arthritis (PsA) is well recognized to be associated with an increased risk of morbidity and mortality related to cardiovascular disease (CVD) that is not fully explained by preexisting traditional CV risk factors (1) (2) (3) . There is an unmet need to precisely identify those patients with PsA who are at greatest risk of developing CV comorbidities. Traditional inflammation markers, such as the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) level, may confound long-term CV risk assessment in patients with systemic inflammatory disease with concomitant subclinical CVD. In addition to the need to elucidate new CV risk biomarkers, equally important is the need to expand our understanding of the mechanisms through which PsA is linked to enhanced pathogenesis of atherosclerotic heart disease. Identification of more sensitive predictors of increased CV risk in PsA patients will allow for improved risk stratification and provide clinical algorithms for implementing preventative measures targeting CVD.
Increased oxidative stress has been implicated in both psoriatic disease and atherosclerosis. High-density lipoprotein (HDL) cholesterol helps to inhibit lipid oxidation in large part through its relationship with a family of antioxidant enzymatic proteins known as paraoxonase 1 (PON1), which are located on HDL particles (4) . Interestingly, it has recently been found that favorable CV outcomes are dependent not just on increasing plasma levels of HDL cholesterol, but also on the antioxidant, antiinflammatory, and antiatherogenic functions of HDL that can be attributed to PON1 enzymatic activity (5) (6) (7) . Diminished PON1 activity is considered to be a biomarker of increased systemic oxidative stress and increased conversion of HDL to a dysfunctional, proinflammatory, and proatherogenic state, and has been associated with the development of CVD (8) . More recently, decreased PON1 enzymatic activity has been shown to be predictive of the development of major CVD-related adverse events (9) .
Recent clinical studies have investigated PON1 activity in systemic inflammatory diseases. A significant reduction in PON1 activity has been reported in patients with rheumatoid arthritis (RA) (10) (11) (12) (13) (14) and patients with systemic lupus erythematosus (SLE) (15) (16) (17) (18) compared to healthy control subjects. In addition, decreasing PON1 activity has been found to be associated with increasing levels of SLE disease activity and end-organ damage. Results from several small observational studies have been conflicting with regard to the PON1 activity levels in patients with psoriasis (PsO) (19) (20) (21) (22) and in those with ankylosing spondylitis (AS) (23) (24) (25) (26) . The present study was the first to characterize serum PON1 enzymatic activity in a psoriatic disease population and to evaluate its association with the extent of psoriatic disease activity and CVD burden. Results are compared between a PsO patient cohort and PsA patient cohort, with healthy subjects used as a control.
PATIENTS AND METHODS
Study population. The study population consisted of adult patients with PsO or PsA (total n = 343) from 2 tertiary academic referral centers participating in the Cardiometabolic Outcome Measures in Psoriatic Arthritis Study (COMPASS). The COM-PASS study was started at the Cleveland Clinic in 2011 to focus on CV health in an ongoing prospective, longitudinal cohort of psoriatic disease patients. Each COMPASS participant provided his or her written informed consent to participate in the study, and approval was obtained from each of the Institutional Review Boards.
PsA was diagnosed in patients according to the Classification of Psoriatic Arthritis (CASPAR) Study Group criteria (27) and was confirmed by board-certified rheumatologists, while PsO was diagnosed by board-certified dermatologists. The control group for this study consisted of 345 healthy adult volunteers who were used for comparison to the psoriatic disease patient cohorts.
Collection of patient data and laboratory tests at baseline. Each patient's age, sex, weight, body mass index (BMI), and waist-to-hip ratio were recorded at baseline, along with current disease-modifying antirheumatic drug (DMARD) treatment regimens. Clinicians' assessments of PsA disease activity included the Disease Activity Score in 28 joints (DAS28) using CRP level and/ or ESR (28) (calculated according to a previously described formula [http://www.4s-dawn.com/DAS28/]), the 74-joint/76-joint tender/swollen joint counts, and the Clinical Disease Activity Index (CDAI) (score scale 0-17) (29). Patient's and clinician's assessments of global disease activity, as well as assessments of the severity of joint and skin disease and pain, were scored on 100-mm visual analog scales (VAS). Patients' general functional status and health-related quality of life (QoL) were evaluated using the Health Assessment Questionnaire (HAQ) disability index (DI) (scale 0-3) (30) Blood samples were obtained from patients at baseline and collected into SST tubes, and stored as serum samples at À80°C for batch determination in PON1 activity assays. Standard-of-care laboratory tests included determination of the ESR, CRP levels, titers of rheumatoid factor and anti-cyclic citrullinated peptide antibodies, fasting blood glucose levels, and lipid profiles.
PON1 activity assays. PON1 activity levels were measured in the PsA and PsO cohorts and compared to the PON1 activity levels in the serum of age-and sex-matched healthy control subjects (patients matched to controls at a ratio of 2:1) to the patients in each cohort. Serum PON1 activity was measured using 2 methods, each of which was classically named after the substrate used to monitor enzymatic function, namely, an assay for serum paraoxonase activity (using paraoxon as the substrate) and an assay for serum arylesterase activity (using phenyl acetate as the substrate) (34) . Details on these methods of analysis have been previously reported by our coinvestigators (9) .
CVD assessments. History of CVD was self-reported by the patient and was defined as a history of myocardial infarction (MI), stroke, or transient ischemic attack, heart or coronary vessel procedures, or peripheral vascular disease prior to enrollment in the COMPASS study. Major CVD risk factors (diabetes, dyslipidemia, hypertension, smoking, and drug intake for CVD) were also documented. The 2002 modified Framingham CVD Risk Score (FRS) from the Third Adult Treatment Panel (ATP III) of the National Cholesterol Education Program (NCEP) was used to calculate each patient's 10-year risk of coronary heart disease (FRS scores, expressed as a percentage) based on reported age, sex, total and HDL cholesterol levels, systolic blood pressure, blood pressure treatment (yes or no), and current smoking status (yes or no). For analysis of CVD risk within cohort subgroups, patients were further divided into 3 tertiles of FRS scores: FRS <10% (low CVD risk), FRS 10-20% (intermediate CVD risk), and FRS ≥20% (high CVD risk). Dyslipidemia was defined as having either elevated triglyceride levels (≥150 mg/dl), reduced HDL cholesterol levels (<40 mg/dl in men and <50 mg/ dl in women), elevated low-density lipoprotein (LDL) cholesterol levels (>130 mg/dl), or treatment with statins.
To assess the extent of CVD burden, patients were identified as having metabolic syndrome based on the 2001 NCEP/ATP III Expert Panel criteria (35). In addition, a subgroup of patients with PsA underwent carotid-duplex high-resolution B mode ultrasound imaging and were screened for carotid intima-media thickening (CIMT) and the presence of plaque defined using the Mannheim consensus criteria (36) . A subgroup of patients underwent a second carotid-duplex ultrasound 2 years later, which was also analyzed.
Statistical analysis. In general, continuous data are summarized as the mean AE SD for normally distributed data, and as the median with interquartile range (IQR) for non-normally distributed data. Categorical data are summarized as the percentage of non-missing data. Comparisons of patient demographics, disease activity, QoL measurements, CVD burden and risk assessments, and laboratory values were made between the PsA and PsO patients using Student's t-test for normally distributed continuous data, Wilcoxon's rank-sum test for non-normally distributed continuous data, and chi-square tests for categorical data. The above data were also described across quartiles of PON1 enzymatic activity. Comparisons across quartiles were made using analysis of variance for normally distributed continuous data, Kruskal-Wallis test for non-normally distributed data, and chisquare test for categorical data. Spearman's rank correlation coefficients were calculated to assess the relationship between PON1 enzymatic activity and various demographic, QoL, and laboratory measures. Odds ratios (ORs) and their corresponding 95% confidence intervals (95% CIs) were generated using logistic regression methods, to assess the relationship between PON1 enzymatic activity and the extent of disease activity.
To assess whether or not differences in PON1 activity were attributable to underlying patient characteristics, patients were age-and sex-matched to a cohort of healthy control subjects. Patients with PsA were first age-and sex-matched at a 2:1 ratio to the healthy control cohort. Subsequently, patients with PsO were age-and sex-matched at a 2:1 ratio to the healthy controls. The 2 sets of matched data were combined and analyzed.
All P values less than 0.05 were considered statistically significant. All analyses were performed using SAS software version 9.3 (SAS Institute). Adjustments for multiple comparisons were not performed.
RESULTS
Characteristics of the patients at baseline. The baseline characteristics of the patients with PsA (n = 198, 51.0% male) and patients with PsO (n = 145, 50.3% male) are shown in Table 1 . Compared to patients with PsO, patients with PsA were older, had a longer average disease duration, were heavier (greater BMI and waist measurements), had worse QoL scores on the HAQ DI and the SF-12 PCS, and had a greater extent of CVD burden based on a higher percentage of PsA patients having concomitant metabolic syndrome, diabetes, hypertension, and patient-reported incidence of CV and vascular surgeries. PON1 activity levels. Unmatched subjects in the PsA cohort (n = 178), PsO cohort (n = 108), and healthy control cohort (n = 349) were found to have significantly different serum arylesterase activity levels (P < 0.001) and showed a similar, but not statistically significant, trend toward differences in serum paraoxonase activity (P = 0.096). In the age-and sex-matched cohorts of patients with PsA (n = 110), patients with PsO (n = 84), and healthy controls (n = 203), the serum levels of arylesterase activity and paraoxonase activity also showed differing distributions in the matched cohorts (Table 2) .
Intercohort comparisons of serum arylesterase and paraoxonase activity levels between the PsA, PsO, and healthy control groups are illustrated in Figure 1 . Mean arylesterase activities were significantly lower both in patients with PsO and in patients with PsA when compared to healthy controls (each P < 0.001). Furthermore, the PsO cohort showed significantly lower mean arylesterase activity when compared to the PsA cohort (P = 0.003). Although the differences were not statistically significant, serum paraoxonase activity showed a trend toward lower median levels in the PsA and PsO cohorts when compared to the healthy control cohort. There was essentially no difference in the median paraoxonase activity between the PsO cohort and the PsA cohort.
Serum paraoxonase activity levels demonstrated a non-normal distribution, with large standard deviations, within the healthy control group (median 767 nmoles/ minute/ml, IQR 419.6-1,463.7) as well as within the PsA group (median 638.5 nmoles/minute/ml, IQR 366.5-1,314) and the PsO group (median 579 nmoles/minute/ml, IQR 371-1,113.5). In contrast, serum arylesterase activity levels demonstrated more of a probability distribution, with smaller standard deviations, in the healthy control group (mean AE SD 144.3 AE 33.42 lmoles/minute/ml) as well as in the patients with PsA (mean AE SD 124.4 AE 33.43 lmoles/minute/ml) and the patients with PsO (mean AE SD 111.0 AE 25.47 lmoles/minute/ml). This difference in distribution of activity levels was similar to that reported in our prior literature for paraoxonase and arylesterase activity in 3,668 patients from a general population at risk for CVD (9) . Correlation of PON1 activity with PsA disease activity. PsA patients with moderate-to-high disease activity (defined as either a DAS28-ESR ≥3.2 or a DAS28-CRP ≥2.67) showed statistically significantly lower serum arylesterase activity than did those with low disease activity (defined as either a DAS28-ESR <3.2 or DAS28-CRP <2.67) (mean AE SD 122.8 AE 30.20 lmoles/minute/ml versus 139.5 AE 32.4 lmoles/minute/ml; P = 0.012). Figure 2 shows the patients with PsA whose serum arylesterase activity fell within the first 2 quartiles. Patients in this population had 4 times greater odds of having moderate-to-high disease activity (for arylesterase activity quartile 1, OR 4.11, 95% CI 1.17-14.4 [P = 0.028]; for arylesterase activity quartile 2, OR 3.66, 95% CI 1.19-11.3 [P = 0.024]). Quartiles of serum paraoxonase activity, however, showed no association with the levels of PsA disease activity.
Furthermore, PsA patients with moderate-to-high disease activity had a greater percentage of CVD risk factors than did those with low disease activity as measured using DAS28 scores. These CVD risk factors included presence of metabolic syndrome (50% versus 25%; P = 0.021), incident carotid artery plaque (50% versus 24%; P = 0.041), and low HDL levels (50% versus 20%; P = 0.006) in PsA patients with moderate-to-high disease activity compared to those with low disease activity.
Although the serum arylesterase activity levels were not significantly different between DMARD-naive and DMARD-treated patients, the levels of serum arylesterase activity did trend lower in those who were DMARD-naive compared to those who were receiving either nonbiologic, biologic, or combination DMARD therapy (mean AE SD 119.2 AE 29.51 lmoles/minute/ml versus 128.7 AE 30.64, 125.2 AE 35.15, and 128.4 AE 28.14 lmoles/minute/ml, respectively).
Correlation of PON1 activity with extent of CVD burden and prevalent CVD. Serum arylesterase activity levels were compared between subgroups of PsA patients based on varying demographic characteristics, disease activity levels, pharmacologic treatments, and preexisting CVD burden, as shown in Table 3 . The PsA cohort showed a statistically significant inverse relationship between lower serum arylesterase activity levels and increasing FRS scores of CVD risk (mean AE SD 126.8 AE 29.01 lmoles/minute/ml in PsA patients with an FRS of <10%, 117.9 AE 37.33 lmoles/minute/ml in PsA patients with an FRS of 10-20%, and 86.6 AE 19.43 lmoles/minutes/ml in PsA patients with an FRS of ≥20%; P = 0.001). A similar, but not statistically significant, inverse relationship was seen in PsA patients with regard to lower median serum paraoxonase activity levels (median 667.0 lmoles/minute/ml, IQR 544.0-268.0) with increasing FRS scores (P = 0.051).
Other subgroups of PsA patients showed statistically significant inverse associations of lower serum arylesterase activity levels with increasing age (P = 0.013), elevated psoriatic disease activity (DAS28 scores, P = 0.012), and increasing CVD burden, including elevated BMI (P = 0.042) and concomitant metabolic syndrome (P = 0.004), as well as presence of plaque on carotid artery ultrasound (P = 0.003) and presence of hypertension (P = 0.014). Arylesterase activity also showed a strong trend toward lower values in those PsA patients with a history of CVD (P = 0.066) and, to a lesser extent, among those with hyperlipidemia and increased CIMT when compared to those without these CVD burdens.
In contrast, serum paraoxonase activity in the PsA cohort did not show any statistically significant differences among these same subgroups (data not shown). Interestingly, analysis of serum paraoxonase and serum arylesterase activity in the patients with PsO divided into the same subgroups as listed in Table 3 also did not show any statistically significant differences with regard to any of the CVD burden and disease risk factors. Figure 2 . Likelihood of serum arylesterase (Aryl) and paraoxonase (PON) activity levels being predictive of low or high disease activity in patients with psoriatic arthritis. Quartile 4 (Q4) (highest disease activity) is the referent. Disease activity was determined using the Disease Activity Score in 28 joints using erythrocyte sedimentation rate (DAS28-ESR) or C-reactive protein level (DAS28-CRP). Low disease activity was defined as a DAS28-ESR of <3.2 or DAS28-CRP of <2.67, while moderate-to-high disease activity was defined as a DAS28-ESR of ≥3.2 or DAS28-CRP of ≥2.67. Results are shown as odds ratios with 95% confidence intervals (95% CIs)
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HUSNI ET AL Table 4 compares the prevalence of moderate-tohigh disease activity and CVD burdens in PsA patients according to quartiles of serum arylesterase activity levels. Compared to patients in the fourth quartile (147-201 lmoles/minute/ml), patients in the first quartile of serum arylesterase activity (53-101 lmoles/minute/ml) had scores indicating more severe functional impairment and disease activity, as determined by the HAQ DI, VAS severity assessments, DLQI, and PsAQoL scores. Furthermore, a larger percentage of patients in the first quartile than in the fourth quartile of serum arylesterase activity had CV comorbidities (metabolic syndrome, hypertension, and hyperlipidemia) and a higher FRS (median 6.0, IQR 2.0-12.0 versus median 2.0, IQR 1.0-4.0; P = 0.005). Patients in the first quartile of serum arylesterase activity also had a higher BMI and greater waist circumference and waist-to-hip ratio, all which indicate a higher risk of obesity. Taken together, these data suggest that there is an inverse association between serum arylesterase activity and the extent of disease activity as well as frequency of CV comorbidities in patients with PsA.
In the PsA cohort, statistically significant inverse correlations were found between serum arylesterase activity levels and the following continuous variables of increasing CVD burden and psoriatic disease severity: age, BMI, HAQ DI, and DLQI QoL scores, waist-to-hip * Except where indicated otherwise, values are the mean AE SD. All percentages are reported as the percentage within each quartile. IQR = interquartile range; HAQ DI = Health Assessment Questionnaire disability index; DLQI = Dermatology Life Quality Index; CVD = cardiovascular disease; BMI = body mass index; ESR = erythrocyte sedimentation rate; HDL = high-density lipoprotein; LDL = low-density lipoprotein.
† P values less than 0.05 were considered significant. ‡ Remission was defined as a Disease Activity Score in 28 joints using C-reactive protein level (DAS28-CRP) of <2.6, low disease activity as a DAS28-CRP of ≥2.6 to <3.2, moderate disease activity as a DAS28-CRP of ≥3.2 to <5.1, and high disease activity as a DAS28-CRP of ≥5.1. § Patient's and clinician's assessments of disease severity on 0-100-mm visual analog scales.
1246 HUSNI ET AL ratios, FRS, disease activity (DAS28 and CDAI scores), and clinician-and patient-reported VAS scores of global disease severity and severity of joint and skin disease (correlations ranging from r = À0.191 to r = À0.309 [P < 0.001 to P < 0.031]). A statistically significant positive correlation was seen between serum arylesterase activity and the SF-12 MCS and SF-12 PCS QoL scores, as well as the HDL and LDL levels (correlations ranging from r = 0.164 to r = 0.373 [P < 0.001 to P < 0.045]). In contrast, there were few correlations between the serum paraoxonase activity levels and any of these variables in the PsA cohort. Moreover, in the PsO cohort, there were no correlations of any of these variables with serum paraoxonase or serum arylesterase activity levels.
DISCUSSION
To our knowledge, this is the first study to evaluate PON1 activity levels in a large cohort of psoriatic disease patients. In addition, we were able to investigate correlations between PON1 activity and measures of systemic inflammation, psoriatic disease activity, and CVD burden in these patient populations. In our study, both patients with PsO and patients with PsA had significantly lower serum arylesterase activity, as determined by assays of PON1 enzymatic activity, when compared to healthy controls (P = 0.001). In particular, in the PsA cohort, we demonstrated that lower arylesterase activity, but not paraoxonase activity, was associated with elevations in disease activity, increasing CVD burden, and worse QoL scores. These associations were not seen in the PsO cohort. Even though epidemiologic studies have shown that PsA patients can be seen as a population at high risk of developing atherosclerosis, these measures of HDLassociated PON1 enzymatic activity may provide the mechanistic link between increased oxidative stress and CVD burden.
Published research suggests that the systemic burden of inflammation, along with oxidative stress, plays a crucial role in enhancing CVD risk in psoriatic diseases. A critical factor in the pathogenesis of atherosclerosis may be the antioxidant, antiinflammatory, and antiatherogenic function of HDL cholesterol, and not its absolute plasma levels (5-7). HDL particles inhibit LDL oxidation and prevent cytokine-induced vascular inflammation, endothelial activation, coagulation, and platelet aggregation. Nevertheless, results of large clinical trials that have been focused on the effects of raising HDL levels have not shown this approach to be cardioprotective (37) . Results of numerous research studies now suggest that measures of the oxidative conversion of the antiatherogenic properties of HDL to proatherogenic properties are a better reflection of the progression of atherosclerotic disease processes than is fluctuation in the levels of HDL alone (38, 39) . These findings and the recent acknowledgement that chronic heart failure may be a form of chronic systemic inflammatory disease of the vasculature (40) (41) (42) suggests that the psoriatic disease process may facilitate an increase in dysfunctional HDL levels, which acts to enhance vascular inflammation, lipid oxidation, plaque growth, and thrombosis as a result of changes in specific enzyme and protein components.
The antioxidant activity of HDL particles can be attributed in large part to the PON1 family of enzymatic proteins, which are structurally and functionally associated with HDL and act to promote its atheroprotective properties by hydrolytic activity toward oxidized lipids. HDL antioxidant activity is best measured by arylesterase and paraoxonase activity assays. Diminished arylesterase and paraoxonase activity is considered to be a biomarker of increased systemic oxidative stress, and leads to conversion of HDL to a dysfunctional proinflammatory and proatherogenic state (8) . Studies in atrisk patients in the general population have shown a relationship between diminished arylesterase activity and increased CVD risk in humans (43) (44) (45) (46) , and one study recently found that this can be predictive of the development of major adverse cardiovascular events (MACEs) (defined as death, nonfatal MI, or nonfatal cerebrovascular accident) (9) . The fact that paraoxonase activity, as compared to arylesterase activity, was a weaker predictor of the development of CVD in these at-risk populations supports our finding that paraoxanase activity levels trended lower but were not significantly decreased in psoriatic disease patients and lacked associations with CVD burden. These data elucidate the role of increased HDL dysfunction in psoriatic disease patients as a possible mechanism underlying the increase in CVD risk. Furthermore, these findings support the notion that serum arylesterase activity, and not serum paraoxanase activity, is a potential biomarker for identifying those at risk for CVD. These findings are supported by studies within other immune-mediated disease states, such as RA and SLE. A study of 45 women with SLE and 48 with RA showed an increased incidence of oxidized, proinflammatory HDL in SLE (45%) with increasing prevalence further up to 86.7% in those with concurrent carotid plaque, as compared to that in patients with RA (incidence of 20%) and that in healthy control subjects (incidence of 4%). In a follow-up study of 276 women with SLE, the presence of proinflammatory HDL contributed up to a 17-fold increase in the likelihood of developing atherosclerosis, suggesting that measures of dysfunctional HDL may be an effective method for the prediction of those patients who could be considered to be at risk for the development of atherosclerosis (47, 48) . In a study of 29 patients with juvenile idiopathic arthritis, decreased arylesterase activity levels and alterations in measures of HDL particle cholesterol transport and endothelial cell migration activities were observed (49) . In patients with PsO, studies have yielded more mixed results, showing that PON1 activity could be either increased (21) or decreased (20) when compared to controls, while another study found no difference in PON1 activity in PsO patients compared to controls (19) . Three reports on PON1 activity in patients with AS were also conflicting, with 1 study showing no difference from controls (23) and 2 studies showing a significant decrease in PON1 activity compared to controls (24, 25) . The present study is the first, to our knowledge, to report on serum PON1 activity levels in patients with PsA and their potential role as a predictor of increased CVD risk in the psoriatic disease population.
In this study, PsA patients with moderate-to-high disease activity demonstrated significantly lower serum arylesterase activity (P = 0.012) when compared to PsA patients with low disease activity (P < 0.05). Lower arylesterase activity was also associated with greater CVD burden, such as worsened FRS scores, increased BMI, concomitant metabolic syndrome, presence of hypertension, current smoking, prior CVD, increased CIMT, and presence of carotid artery plaque (each P < 0.05). Decreasing arylesterase activity levels also showed a significant linear correlation (P < 0.04) with lower QoL scores (HAQ DI, SF-12, and DLQI). These results are consistent with those in previous studies demonstrating elevated markers of subclinical atherosclerosis, such as measurements of CIMT, in PsA patients with high disease activity (50, 51) .
The group of PsA patients with values in the lowest quartile of serum arylesterase activity had significantly worse disease severity, had a lower percentage with disease in remission (P < 0.04), and had lower QoL as measured by the PsAQoL, HAQ DI, and SF-12 scores (P < 0.05). Patients in the lowest quartile of serum arylesterase activity also showed higher CVD burden, manifested by significantly higher FRS scores, higher waist-to-hip ratios, and higher frequencies of metabolic syndrome, hypertension, and hyperlipidemia (P < 0.05).
The association of PON1 activity with apolipoprotein A-I (Apo A-I) and HDL levels is very complex, and the assumption that PON1 activity is solely associated with HDL levels is being challenged by research. PON1 (arylesterase) activity is an independent determinant of serum HDL and Apo A-I concentrations. This has been measured in studies assessing correlations of paraoxonase and arylesterase levels with systemic oxidative stress and prospective CVD risk, demonstrating a potential mechanism for the atheroprotective function of PON1. These activity measures have been validated as being significantly associated with the antioxidant effect of PON1. Measuring changes in PON1 mass via Western blotting or enzyme-linked immunosorbent assay (ELISA) is a relatively poor indicator of PON1 activity, due to the fact that PON1 is known to be highly susceptible to inactivation by oxidative stress.
A previous study by our group and others provided direct evidence to indicate that a PON1 gene polymorphism can significantly affect paraoxanase activity levels within the general population (43) . Arylesterase activity, however, showed much lower genetic determination, suggesting that arylesterase activity may serve as a more sensitive predictor than paraoxonase activity for identifying increased CVD risk in psoriatic disease patients, and is most likely the cause for the large standard deviation in paraoxonase activity levels reported in PsA and PsO cohorts (9, (43) (44) (45) . Another potential explanation may be that PON1 is known to be susceptible to oxidative inactivation, and PON1 activity measures are a better predictor of oxidative stress and CVD risks than is ELISA (mass-based) for measurement of PON1. Indeed, we have previously shown that PON1, myeloperoxidase (MPO) (a leukocytederived enzyme that generates reactive oxidant species), and HDL form a functional ternary complex, with MPO activity directly impacting and inhibiting PON1, and conversely, the presence of PON1 impacting and inhibiting MPO activity (i.e., there is reciprocal regulation of activity).
Paradoxically, even though patients in the PsA cohort had a greater preponderance of factors indicative of elevated CVD risk when compared to patients in the PsO cohort, such as worse QoL as measured using the HAQ DI, DLQI, and SF-12 PCS (P < 0.001), greater BMI (P = 0.01), higher CRP levels (P = 0.001), and concomitant metabolic syndrome, hypertension, and diabetes (P < 0.04), as well as a higher frequency of prior CV procedures (P = 0.045), the PsO cohort had a significantly lower serum arylesterase activity level than did the PsA cohort (mean AE SD 112.8 AE 26.5 lmoles/minute/ml versus 124.9 AE 31.6 lmoles/minute/ml; P < 0.001). In addition to these baseline cohort differences, the strong statistically significant correlations between serum arylesterase activity levels and disease activity measures, history of CVD burden, and lower QoL measures in the PsA cohort were not seen in the PsO cohort, nor were they seen in the PsO cohort in relation to serum paraoxonase enzymatic activity levels.
While these differences may be partially explained by the longer disease durations (P = 0.001) and average older age (P = 0.002) of patients in the PsA group compared to the PsO group, another explanation may be that disease activity was low in the PsA cohort. The PsA cohort had significantly higher DMARD use when compared to the PsO cohort. In the PsA cohort,~70% of patients were being treated with DMARDs (with~50% of those being biologic DMARDs), while only 24% of the PsO cohort were being treated with DMARDs. As a result, the PsA cohort had a relatively low disease activity level, with fewer than 5% of patients displaying high disease activity (DAS28-CRP >5.1). Ongoing studies investigating the effects of biologic and nonbiologic DMARDs on measures of oxidative stress, endothelial dysfunction, and CVD risk may eventually explain our paradoxical findings in psoriatic disease. It is also yet to be determined whether these short-term measures of PON1 activity will help predict the risk of incident MACEs longitudinally.
The present study would have been strengthened by the use of a PsA-specific composite measure. Since there is no consensus with regard to the optimal composite measure for PsA at this time, the DAS28 was used in our study. Although paraoxone and phenyl acetate have been validated as relevant substrates in PON1 activity assays, another limitation is that other potential PON1 activity substrates, such as lactones, which are considered physiologically relevant to PON1 activity, were not used.
In summary, identifying clinically useful and relevant measures of HDL dysfunction through measures of PON1 activity may lead to potential risk stratification, a strategy that is needed in caring for patients with psoriatic diseases. Clinical research supports the association between PON1 activity and CVD in the general population, and suggests that there is a link to heightened oxidative stress and psoriatic disease. In this study, we focused on biomarkers of the oxidative stress-induced dysfunction of those constituents of HDL that play antiinflammatory and antioxidant roles in psoriatic disease.
Our results show that both the serum arylesterase and serum paraoxonase enzymatic activity levels are decreased in PsO and PsA patients relative to healthy controls. However, only arylesterase activity levels correlated with disease severity and CVD burden in the PsA cohort. Arylesterase activity, and not paraoxanase activity, was a more sensitive predictor of the increased CVD risk observed in PsA patients, most likely due to the fact that paraoxanase activity levels within the general population are a greater genetic determinant than are arylesterase activity levels. The lower PON1 activity levels seen in PsO patients as compared to PsA patients may be a reflection of inherent mechanistic differences in the preatherosclerotic pathology of the 2 diseases. These data therefore suggest that serum arylesterase activity may be used as an additional CV risk stratification tool that would allow for earlier implementation of CVD preventative diagnostics and therapeutics in subsets of PsA patient populations.
